Cochlear (COH) Hisse Özeti
Cochlear Limited, dünya çapında çocuklar ve yetişkinler için implante edilebilir işitme çözümleri sunmaktadır. Daha fazla detay
| Kar Tanesi Skoru | |
|---|---|
| Değerleme | 4/6 |
| Gelecekteki Büyüme | 1/6 |
| Geçmiş Performans | 2/6 |
| Finansal Sağlık | 6/6 |
| Temettüler | 3/6 |
COH Community Fair Values
Create NarrativeSee what 72 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
AU$70
FV
82.7% aşırı değerlenmiş içsel indirim0.14%
Revenue growth p.a.
195
users have viewed this narrative0users have liked this narrative
1users have commented on this narrative
6users have followed this narrative
Cochlear Limited Rakipler
Fiyat Geçmişi ve Performans
| Tarihsel hisse senedi fiyatları | |
|---|---|
| Güncel Hisse Fiyatı | AU$127.86 |
| 52 Haftanın En Yüksek Seviyesi | AU$319.56 |
| 52 Haftanın En Düşük Seviyesi | AU$88.74 |
| Beta | 0.26 |
| 1 Aylık Değişim | 27.29% |
| 3 Aylık Değişim | -26.14% |
| 1 Yıllık Değişim | -57.48% |
| 3 Yıllık Değişim | -42.38% |
| 5 Yıllık Değişim | -47.13% |
| Halka arzdan bu yana değişim | 4,234.24% |
Son Haberler & Güncellemeler
Anlatı Güncellemesi • Jul 02
COH: Hospital Bottlenecks And Weaker Referrals Will Pressure Earnings Expectations
The analyst price target for Cochlear has been revised from A$210 to A$95, reflecting updated expectations for revenue growth, profit margins, the discount rate and future P/E as outlined in recent Street research from multiple analysts. Analyst Commentary Recent Street research on Cochlear highlights a more cautious tone despite mixed rating actions, with several bearish analysts questioning how well the current share price lines up with the revised A$95 target and the company’s execution risks.Analiz Makalesi • Jun 19
Cochlear (ASX:COH) Shares Could Be 44% Below Fair Value After 2026 Guidance Cut
Cochlear (ASX:COH) is back in focus after the company issued a 2026 guidance downgrade, prompting a reset in expectations for both the stock and the broader premium ASX healthcare segment. See our latest analysis for Cochlear. The 2026 guidance downgrade comes after a sharp rebound in Cochlear’s share price over the past month, with a 30 day share price return of 24.66%. However, that short term strength contrasts with a much weaker backdrop, including a 90 day share price decline of 28.23%...
Anlatı Güncellemesi • Jun 18
COH: Margin Resilience And Core Franchise Strength Will Support Future Upside
The analyst price target for Cochlear has been adjusted slightly lower to A$124.40. Analysts attribute this change to modest tweaks in the discount rate, revenue growth, profit margin and future P/E assumptions following recent mixed research updates from major brokers.Anlatı Güncellemesi • Jun 03
COH: Margin Resilience And Temporary Volume Weaknesses Will Support Future Upside
The analyst price target for Cochlear has eased slightly from about A$126.08 to A$124.60, as analysts factor in more moderate revenue growth expectations alongside marginally stronger profit margins and a slightly lower assumed future P/E, following mixed recent research views. Analyst Commentary Bullish Takeaways Bullish analysts see room for upside if Cochlear can deliver on revenue expectations while maintaining the marginally stronger profit margins now being reflected in models.Recent updates
Anlatı Güncellemesi • Jul 02
COH: Hospital Bottlenecks And Weaker Referrals Will Pressure Earnings Expectations
The analyst price target for Cochlear has been revised from A$210 to A$95, reflecting updated expectations for revenue growth, profit margins, the discount rate and future P/E as outlined in recent Street research from multiple analysts. Analyst Commentary Recent Street research on Cochlear highlights a more cautious tone despite mixed rating actions, with several bearish analysts questioning how well the current share price lines up with the revised A$95 target and the company’s execution risks.Analiz Makalesi • Jun 19
Cochlear (ASX:COH) Shares Could Be 44% Below Fair Value After 2026 Guidance Cut
Cochlear (ASX:COH) is back in focus after the company issued a 2026 guidance downgrade, prompting a reset in expectations for both the stock and the broader premium ASX healthcare segment. See our latest analysis for Cochlear. The 2026 guidance downgrade comes after a sharp rebound in Cochlear’s share price over the past month, with a 30 day share price return of 24.66%. However, that short term strength contrasts with a much weaker backdrop, including a 90 day share price decline of 28.23%...Anlatı Güncellemesi • Jun 18
COH: Margin Resilience And Core Franchise Strength Will Support Future Upside
The analyst price target for Cochlear has been adjusted slightly lower to A$124.40. Analysts attribute this change to modest tweaks in the discount rate, revenue growth, profit margin and future P/E assumptions following recent mixed research updates from major brokers.Anlatı Güncellemesi • Jun 03
COH: Margin Resilience And Temporary Volume Weaknesses Will Support Future Upside
The analyst price target for Cochlear has eased slightly from about A$126.08 to A$124.60, as analysts factor in more moderate revenue growth expectations alongside marginally stronger profit margins and a slightly lower assumed future P/E, following mixed recent research views. Analyst Commentary Bullish Takeaways Bullish analysts see room for upside if Cochlear can deliver on revenue expectations while maintaining the marginally stronger profit margins now being reflected in models.Anlatı Güncellemesi • May 09
COH: Steadier Growth Assumptions Will Support Future Upside If Execution Holds
The updated analyst price target for Cochlear has shifted from A$239.95 to A$126.08 as analysts incorporate more moderate assumptions for revenue growth, profit margins and future P/E. This reflects mixed recent research views from Citi and Morgan Stanley.
Yeni Anlatı • May 09
Cochlear’s Crossroads: Temporary Setback or Structural Shift?
Cochlear Limited is an interesting company. It is a medical technology business with a specific focus on implantable hearing solutions.Anlatı Güncellemesi • Apr 21
COH: VA Access Expansion Will Support Future Upside Despite Slight Model Adjustments
The Analyst Price Target for Cochlear has been adjusted slightly lower to A$239.95 from A$244.58, as analysts now factor in modestly softer revenue growth, profit margin and future P/E assumptions, along with a slightly higher discount rate. Valuation Changes Fair Value: adjusted slightly lower from A$244.58 to A$239.95.Anlatı Güncellemesi • Apr 04
COH: VA Access Expansion And Upgraded Coverage Will Underpin Future Upside
Analysts have slightly adjusted their price target for Cochlear to A$244.58 from A$245.91. This reflects updated assumptions around discount rates and valuation multiples, while core growth and profitability expectations remain broadly unchanged.Anlatı Güncellemesi • Mar 21
COH: VA Access Expansion Will Support Future Upside Potential
Analysts have adjusted their price target on Cochlear slightly lower to A$245.91 from A$250.59, reflecting modest tweaks to assumptions around the discount rate, revenue growth, profit margins and future P/E following recent research updates. Analyst Commentary Bullish Takeaways Bullish analysts see the revised A$245.91 target as still supportive of upside potential relative to recent trading levels, suggesting the core earnings story remains intact despite the small adjustment.Anlatı Güncellemesi • Mar 06
COH: Steady Assumptions And New Access Channels Will Support Future Upside Potential
Analysts have reaffirmed their A$250.59 price target for Cochlear, citing recent research that supports steady assumptions around the discount rate, revenue growth, profit margins and future P/E expectations. Analyst Commentary Recent research behind the reaffirmed A$250.59 price target highlights a mix of supportive factors and watchpoints that matter for Cochlear's valuation and execution risk.Yeni Anlatı • Mar 01
Cloud And R&D Investment Will Pressure Margins While Long Term Hearing Demand Supports Stability
Catalysts About Cochlear Cochlear develops and manufactures hearing implant systems for people with severe to profound hearing loss. What are the underlying business or industry changes driving this perspective?Anlatı Güncellemesi • Feb 20
COH: Reset Expectations And Product Adoption Will Support Future Upside Potential
Analysts have trimmed their Cochlear price target from A$301.76 to A$250.59 as they factor in slightly lower revenue growth assumptions, a marginally higher discount rate, modestly softer profit margin expectations and a reduced future P/E multiple, as highlighted in recent Street research, including the latest upgrade at RBC Capital. Analyst Commentary Recent Street commentary around Cochlear focuses on how current expectations stack up against its A$250.59 target price and what needs to go right, or wrong, for that valuation to hold.Analiz Makalesi • Feb 16
Cochlear (ASX:COH) Has Affirmed Its Dividend Of A$2.15
Cochlear Limited's ( ASX:COH ) investors are due to receive a payment of A$2.15 per share on 13th of April. This means...Analiz Makalesi • Feb 15
Some Confidence Is Lacking In Cochlear Limited (ASX:COH) As Shares Slide 26%
Cochlear Limited ( ASX:COH ) shareholders that were waiting for something to happen have been dealt a blow with a 26...
Yeni Anlatı • Feb 13
Hearing Health Tailwinds And Cloud Capabilities Will Support Multi Year Earnings Expansion
Catalysts About Cochlear Cochlear develops and manufactures implantable hearing solutions for people with severe to profound hearing loss. What are the underlying business or industry changes driving this perspective?Analiz Makalesi • Feb 06
Here's Why We Think Cochlear (ASX:COH) Might Deserve Your Attention Today
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...Anlatı Güncellemesi • Feb 05
COH: Execution Upside And Premium P/E Will Underpin Future Upside Potential
Analysts have trimmed their price target on Cochlear to about A$302 from roughly A$305, reflecting a slightly higher discount rate, modestly lower revenue growth assumptions, and a small uplift in expected profit margins and future P/E multiples. Analyst Commentary Recent research adjustments on Cochlear point to a generally constructive stance, with the trimmed price target tied to updated assumptions rather than a material change in the long term story.Analiz Makalesi • Jan 11
Investors Shouldn't Overlook Cochlear's (ASX:COH) Impressive Returns On Capital
If you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...Analiz Makalesi • Nov 18
Risks To Shareholder Returns Are Elevated At These Prices For Cochlear Limited (ASX:COH)
When close to half the companies in Australia have price-to-earnings ratios (or "P/E's") below 21x, you may consider...Analiz Makalesi • Oct 14
Does Cochlear (ASX:COH) Deserve A Spot On Your Watchlist?
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...Analiz Makalesi • Sep 28
We Think Cochlear (ASX:COH) Might Have The DNA Of A Multi-Bagger
Finding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...Anlatı Güncellemesi • Sep 19
Aging Population Will Spur Cochlear Implant Adoption Worldwide
Cochlear’s modestly lower consensus price target predominantly reflects a slight reduction in forecast revenue growth, resulting in a revised fair value estimate of A$305.38. What's in the News Cochlear extended its share buyback plan duration to August 28, 2026.Analiz Makalesi • Aug 26
Cochlear (ASX:COH) Is Due To Pay A Dividend Of A$2.15
Cochlear Limited's ( ASX:COH ) investors are due to receive a payment of A$2.15 per share on 13th of October. This...Anlatı Güncellemesi • Aug 19
New Cochlear Implant Launch And Market Expansion Will Strengthen Future Prospects
Cochlear’s consensus price target has been revised upward, primarily reflecting improved revenue growth forecasts and a slight increase in net profit margin, resulting in a new fair value estimate of A$309.91. What's in the News FDA approved Cochlear’s Nucleus Nexa System, the first smart cochlear implant system with upgradeable firmware, allowing recipients to access future innovations through both the implant and sound processor.Analiz Makalesi • Jul 16
Cochlear Limited's (ASX:COH) Shares May Have Run Too Fast Too Soon
When close to half the companies in Australia have price-to-earnings ratios (or "P/E's") below 18x, you may consider...
Yeni Anlatı • Feb 23
New Cochlear Implant Launch And Market Expansion Will Strengthen Future Prospects
Focus on adult and senior markets in developed countries could drive revenue and net margin growth through increased sales volume.Hissedar Getirileri
| COH | AU Medical Equipment | AU Pazar | |
|---|---|---|---|
| 7D | 5.6% | 5.2% | 0.2% |
| 1Y | -57.5% | -41.3% | 2.2% |
Getiri vs. Endüstri: COH geçen yıl % -41.3 oranında getiri sağlayan Australian Medical Equipment sektörünün gerisinde kaldı.
Getiri vs Piyasa: COH geçen yıl % 2.2 oranında getiri sağlayan Australian Piyasasının altında performans gösterdi.
Fiyat Oynaklığı
| COH volatility | |
|---|---|
| COH Average Weekly Movement | 12.6% |
| Medical Equipment Industry Average Movement | 9.8% |
| Market Average Movement | 9.7% |
| 10% most volatile stocks in AU Market | 17.0% |
| 10% least volatile stocks in AU Market | 4.0% |
İstikrarlı Hisse Senedi Fiyatı: COH son 3 ayda Australian piyasasına kıyasla önemli bir fiyat oynaklığı yaşamadı.
Zaman İçindeki Volatilite: COH 'nin haftalık oynaklığı geçtiğimiz yıl boyunca 7% dan 13% a yükseldi, ancak hâlâ Australian hisselerinin %75'inden düşük.
Şirket Hakkında
| Kuruldu | Çalışanlar | CEO | Web sitesi |
|---|---|---|---|
| 1981 | 5,500 | Dig Howitt | www.cochlear.com |
Cochlear Limited, dünya çapında çocuklar ve yetişkinler için implante edilebilir işitme çözümleri sunmaktadır. Şirket koklear implant sistemleri, ses işlemcisi yükseltmeleri, kemik iletim sistemleri ve diğer ürünleri sunmaktadır. Ayrıca Nucleus ses işlemcileri, akıllı bimodal işitme çözümü ve Nucleus implantları dahil olmak üzere koklear nükleus sistemleri; Baha 6 max ses işlemcisi ve Baha implantından oluşan koklear Baha sistemleri ve kablosuz cihazlar ve Nucleus su geçirmez aksesuarlar gibi aksesuarlar da sunmaktadır.
Cochlear Limited Temel Bilgiler Özeti
| COH temel i̇stati̇sti̇kler | |
|---|---|
| Piyasa değeri | AU$8.36b |
| Kazançlar(TTM) | AU$345.30m |
| Gelir(TTM) | AU$2.34b |
24.2x
F/K Oranı3.6x
P/S OranıCOH aşırı değerli mi?
Gerçeğe Uygun Değer ve değerleme analizine bakınızKazanç ve Gelir
| COH gelir tablosu (TTM) | |
|---|---|
| Gelir | AU$2.34b |
| Gelir Maliyeti | AU$636.90m |
| Brüt Kâr | AU$1.70b |
| Diğer Giderler | AU$1.36b |
| Kazançlar | AU$345.30m |
Son Raporlanan Kazançlar
Dec 31, 2025
Sonraki Kazanç Tarihi
Aug 18, 2026
| Hisse başına kazanç (EPS) | 5.28 |
| Brüt Marj | 72.76% |
| Net Kâr Marjı | 14.77% |
| Borç/Özkaynak Oranı | 0.7% |
COH uzun vadede nasıl bir performans gösterdi?
Geçmiş performansı ve karşılaştırmayı görünTemettüler
3.4%
Mevcut Temettü Verimi81%
Ödeme OranıŞirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/07/06 00:35 |
| Gün Sonu Hisse Fiyatı | 2026/07/06 00:00 |
| Kazançlar | 2025/12/31 |
| Yıllık Kazançlar | 2025/06/30 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları GitHub sayfamızda mevcuttur; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube'da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
Cochlear Limited 26 Bu analistlerden 16, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Saul Hadassin | Barrenjoey Markets Pty Limited |
| Stuart Roberts | Bell Potter |
| Elisabeth Decou Clive | Bernstein |